Ye Li

Dr. Ye Li

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Cell Stem Cell
Verified
Journal Article
Closed access
YLYe Li
Ye Li
DHDavid L. Hermanson
David L. Hermanson
BMBranden S. Moriarity
Branden S. Moriarity
DKDan S. Kaufman
Dan S. Kaufman

18 January 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DMDavid Marin
David Marin
YLYe Li
Ye Li
RBRafet Basar
Rafet Basar
HRHind Rafei
Hind Rafei
MDMay Daher
May Daher
KRKatayoun Rezvani
Katayoun Rezvani
There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19+ B cell malignancies. The primary objectives were safety and efficacy, defined as day 30 overall response (OR). Secondary objectives included day 100 response, progression-free survival, overall survival and CAR19/IL-15 NK cell persistence. No notable toxicities such as cytokine release syndrome, neurotoxicity or graft-versus-host disease were observed. The day 30 and day 100 OR rates were 48.6% for both. The 1-year overall survival and progression-free survival were 68% and 32%, respectively. Patients who achieved OR had higher levels and longer persistence of CAR-NK cells. Receiving CAR-NK cells from a cord blood unit (CBU) with nucleated red blood cells ≤ 8 × 107 and a collection-to-cryopreservation time ≤ 24 h was the most significant predictor for superior outcome. NK cells from these optimal CBUs were highly functional and enriched in effector-related genes. In contrast, NK cells from suboptimal CBUs had upregulation of inflammation, hypoxia and cellular stress programs. Finally, using multiple mouse models, we confirmed the superior antitumor activity of CAR/IL-15 NK cells from optimal CBUs in vivo. These findings uncover new features of CAR-NK cell biology and underscore the importance of donor selection for allogeneic cell therapies. ClinicalTrials.gov identifier: NCT03056339.

15 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
HSHila Shaim
Hila Shaim
MSMayra Shanley
Mayra Shanley
RBRafet Basar
Rafet Basar
MDMay Daher
May Daher
JGJoy Gumin
Joy Gumin
KRKatayoun Rezvani
Katayoun Rezvani
Glioblastoma multiforme (GBM), the most aggressive brain cancer, recurs because glioblastoma stem cells (GSCs) are resistant to all standard therapies. We showed that GSCs, but not normal astrocytes, are sensitive to lysis by healthy allogeneic natural killer (NK) cells in vitro. Mass cytometry and single-cell RNA sequencing of primary tumor samples revealed that GBM tumor–infiltrating NK cells acquired an altered phenotype associated with impaired lytic function relative to matched peripheral blood NK cells from patients with GBM or healthy donors. We attributed this immune evasion tactic to direct cell-to-cell contact between GSCs and NK cells via αv integrin–mediated TGF-β activation. Treatment of GSC-engrafted mice with allogeneic NK cells in combination with inhibitors of integrin or TGF-β signaling or with TGFBR2 gene–edited allogeneic NK cells prevented GSC-induced NK cell dysfunction and tumor growth. These findings reveal an important mechanism of NK cell immune evasion by GSCs and suggest the αv integrin/TGF-β axis as a potentially useful therapeutic target in GBM.

29 September 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YLYe Li
Ye Li
RBRafet Basar
Rafet Basar
GWGuohui Wang
Guohui Wang
ELEnli Liu
Enli Liu
JMJudy S. Moyes
Judy S. Moyes
KRKatayoun Rezvani
Katayoun Rezvani

28 July 2023 in Science Advances
Verified
Journal Article
Open access
LLLi Li
Li Li
VMVakul Mohanty
Vakul Mohanty
JDJinzhuang Dou
Jinzhuang Dou
YHYuefan Huang
Yuefan Huang
PBPinaki P. Banerjee
Pinaki P. Banerjee
KRKatayoun Rezvani
Katayoun Rezvani
Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is promising, with early-phase clinical studies showing encouraging responses. However, the transcriptional signatures that control the fate of CAR-NK cells after infusion and factors that influence tumor control remain poorly understood. We performed single-cell RNA sequencing and mass cytometry to study the heterogeneity of CAR-NK cells and their in vivo evolution after adoptive transfer, from the phase of tumor control to relapse. Using a preclinical model of noncurative lymphoma and samples from a responder and a nonresponder patient treated with CAR19/IL-15 NK cells, we observed the emergence of NK cell clusters with distinct patterns of activation, function, and metabolic signature associated with different phases of in vivo evolution and tumor control. Interaction with the highly metabolically active tumor resulted in loss of metabolic fitness in NK cells that could be partly overcome by incorporation of IL-15 in the CAR construct.

4 April 2025 in Nature Medicine
Verified
Journal Article
Closed access
YNYago Nieto
Yago Nieto
PBPinaki Banerjee
Pinaki Banerjee
IKIndreshpal Kaur
Indreshpal Kaur
RBRafet Basar
Rafet Basar
YLYe Li
Ye Li
KRKatayoun Rezvani
Katayoun Rezvani